Venus Remedies Ltd Financials
Company Logo

Venus Remedies Ltd Financial Statement

Venus Remedies Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue177.73
Operating Expense156.77
Net Profit9.26
Net Profit Margin5.21
Earning Per Share6.92
EBIDTA19.13
Effective Tax Rate17.75

Venus Remedies Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual575.21
Operating Expenses Annual514.32
Operating Profit Annual72.21
Interest AnnualTBA
Depreciation16.51
Net Profit Annual30.50
Tax Annual16.15

Venus Remedies Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning20.07
Cash Flow from Operations35.38
Cash Flow from Investing-6.94
Cash Flow from FinancingTBA
Cash Flow at the End48.51

Venus Remedies Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)12.55
PBIT Margin (%)8.11
PBT Margin (%)8.11
Net PROFIT Margin (%)5.30
Return On Networth / Equity (%)6.18
Return On Networth /Employed (%)8.61
Return On Assets (%)5.62
Total Debt / Equity (X)0.08
Asset Turnover Ratio (%)1.06

Venus Remedies Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual202.76
Total Current Assets Annual361.00
Non Current Assets Annual280.26
Total Shareholders Funds Annual508.59
Total Assets Annual641.26

Venus Remedies Ltd Earning Calls

EPS (INR)

Expected

2.63

Reported

2.63

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 1.10%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Venus Remedies Ltd has a market capitalization of 436.30 Cr. Value Research classifies it as a Small-Cap company.
Yes, Venus Remedies Ltd is debt-free with a debt-to-equity ratio of 0.08.
In FY 2023 , Venus Remedies Ltd recorded a total revenue of approximately 575.21 Cr marking a significant milestone in the company's financial performance.
Venus Remedies Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and -0.0% annually, respectively..
Venus Remedies Ltd's current PE ratio is 14.30.
Venus Remedies Ltd's ROCE averaged 8.5% from the FY ending March 2022 to 2024, with a median of 8.5%. It peaked at 9.2% in March 2022, reflecting strong capital efficiency over the period..
Venus Remedies Ltd's latest EBIT is Rs. 46.65 Cr, surpassing the average EBIT of Rs. 43.88 Cr over the 5 years..